VISSIT Intracranial Stent Study for Ischemic Therapy

NCT ID: NCT00816166

Last Updated: 2015-02-20

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 125 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2014-06-30

Brief Summary

The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.

A secondary objective of this study is to evaluate the impact of stenting in the neurovasculature to treat cerebral ischemia on other outcomes such as hospital length of stay, charges, and costs.

Detailed Description

1.1 Study Hypothesis Treatment of cerebral or retinal ischemia due to plaque in the neurovasculature using the PHAROS Vitesse Stent System plus medical therapy will provide additional clinical benefit over medical therapy alone.

1.2 Primary Effectiveness Endpoint

The primary effectiveness endpoint consists of a composite of the two following outcomes:

• Stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization
• Hard TIA in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 post-randomization

1.3 Safety Outcomes

Safety outcomes to be collected and reported as part of the overall risk-to-benefit profile for this device are:

• Stroke in any territory within 30 days of randomization
• Death from any cause within 30 days of randomization
• Hard TIA in any territory occurring after a 24 hour post-procedure stabilization period (days 2-30) since the recovery from anesthesia can mask accurate assessment of possible TIA symptoms.
• Intracranial hemorrhage within 30 days of randomization

1.4 Other Outcomes

• Stent Success - PHAROS Vitesse stent deployed across target lesion with residual stenosis 0-20%
• Percentage of Stent Group Subjects with any (symptomatic or asymptomatic) in-stent restenosis ≥ 70% confirmed by angiogram at 12 months
• Percentage of Stent Group Subjects with symptomatic in-stent restenosis ≥ 70% confirmed by angiogram at 12 months
• Percentage of Medical Therapy Group Subjects with interventional procedure (e.g., angioplasty or stent) at 12 months
• Comparison of NIHSS scores between treatment arms
• Comparison of mRS scores between treatment arms

Conditions

Ischemic Stroke; Transient Ischemic Attack

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Stent Group

Medical therapy + PHAROS Vitesse neurovascular stent ("Stent Group")

Group Type: EXPERIMENTAL

Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)

Intervention Type: DEVICE

Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]

Medical Therapy Group

Medical therapy alone ("Medical Therapy Group")

Group Type: ACTIVE_COMPARATOR

Aspirin and Clopidogrel (Medical therapy)

Intervention Type: DRUG

Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]

Interventions

Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)

Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]

Intervention Type: DEVICE

Aspirin and Clopidogrel (Medical therapy)

Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]

Intervention Type: DRUG

Other Intervention Names

Pharos Vitesse Neurovascular Stent System; Asprin; Clopidogrel; Plavix(r); Aspirin; Clopidogrel; Plavix(r)

Eligibility Criteria

Inclusion Criteria

1. Subject has at least one neurovascular lesion (70-99%) stenosis [internal carotid, middle cerebral, vertebral artery (C4-BA), and/or basilar artery] symptomatic with a hard TIA or stroke attributable to the territory of the lesion within the past 30 days. An intracranial tandem lesion (50-99%) stenosis may be treated if normal artery segment is sufficient length to avoid overlapping stents.

2. Target vessel diameter / lesion length measurements are within one of the below per angiogram:

• Vessel diameter is ≥ 2.0 mm and < 2.5 mm / lesion length is ≤ 16 mm, or
• Vessel diameter is ≥ 2.5 mm and < 3.0 mm / lesion length is ≤ 18 mm, or
• Vessel diameter is ≥ 3.0 mm and < 4.5 mm / lesion length is ≤ 26 mm, or
• Vessel diameter is ≥ 4.5 mm and ≤ 5.0 mm / lesion length is ≤ 31 mm

3. Subject has normal artery adjacent to each stenosis; diameter 2.0 mm - 5.0 mm

4. Subject age is 18-85 years

5. Life expectancy is at least 2 years

6. Subject 's mRS score is ≤ 3

7. Subject is available for study follow-up visits (e.g., lives within 3 hours of research center)

8. Subject is willing and cognitively able to provide Informed Consent (consent may be indicated verbally and signed by neutral witness if stroke has impaired hand or visual function)

Exclusion Criteria

1. Subject has contraindications for balloon expandable stent, e.g.

• Extreme tortuosity at, or proximal to, target lesion,
• More than 2 lesions with > 50% stenosis (including vertebral ostia and common carotid disease),
• Carotid or vertebral dissection

2. CT scan or MRI evidence of any of the following:

• Intracranial hemorrhage of type PH1 or PH2
• Subdural or epidural hemorrhage
• Mass effect, or
• Intracranial tumor (except small meningioma)

3. Subject has a previous stent in the territory of the target lesion(s)

4. Subject has a previous coil or clip placed in the territory of the target lesion within 6 months

5. Subject has a potential source of cardiac embolism requiring anticoagulation therapy (e.g., atrial fibrillation, intracardiac thrombus or vegetation, significant mitral stenosis, mechanical heart valve, congestive heart failure with EF <30%, or endocarditis)

6. Subject has concurrent intracranial pathology, e.g.

• Moyamoya
• Vasculitis documented by biopsy results
• Ruptured Aneurysm
• Unruptured aneurysm > 7mm

7. Subject has uncontrolled hypertension (systolic >185 mmHg or diastolic >110 mmHg)

8. Hemoglobin < 10 g/dL; platelet count < 100,000; or INR > 1.5 (e.g., use of warfarin)

9. Subject has an uncorrectable bleeding diathesis

10. Subject's neurological status is unstable and rapidly declining (NIHSS score increased > 4 points within 48 hours prior to randomization)

11. Subject has a contraindication for combination antithrombotic treatment (e.g., clopidogrel and aspirin) such as peptic ulcer disease

12. Subject history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)

13. Subject has a known history contraindicating contrast dye or iodine (vs. sensitivity which can be safely controlled by antihistamine, steroid, etc.)

14. Subject is pregnant or plans to become pregnant in the next 12 months

15. Myocardial infarction within past 3 months

16. Treatment with tPA or other thrombolytic agent within 48 hours prior to randomization

17. Major surgery or trauma within 2 weeks prior to randomization

18. Enrollment in another investigational device or drug study that may confound the results

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Codman & Shurtleff

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

Berkefeld J, Hamann GF, du Mesnil R, Kurre W, Steinmetz H, Zanella FE, Sitzer M. [Endovascular treatment for intracranial stenoses. A common statement by neurologists and neuroradiologists]. Nervenarzt. 2006 Dec;77(12):1444-55. doi: 10.1007/s00115-006-2182-z. German.

Reference Type: BACKGROUND

PMID: 17119891 (View on PubMed)

Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16. doi: 10.1056/NEJMoa043033.

Reference Type: BACKGROUND

PMID: 15800226 (View on PubMed)

Cruz-Flores S, Diamond AL. Angioplasty for intracranial artery stenosis. Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD004133. doi: 10.1002/14651858.CD004133.pub2.

Reference Type: BACKGROUND

PMID: 16856032 (View on PubMed)

Derdeyn CP, Chimowitz MI. Angioplasty and stenting for atherosclerotic intracranial stenosis: rationale for a randomized clinical trial. Neuroimaging Clin N Am. 2007 Aug;17(3):355-63, viii-ix. doi: 10.1016/j.nic.2007.05.001.

Reference Type: BACKGROUND

PMID: 17826637 (View on PubMed)

Fiorella D, Chow MM, Anderson M, Woo H, Rasmussen PA, Masaryk TJ. A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease. Neurosurgery. 2007 Aug;61(2):236-42; discussion 242-3. doi: 10.1227/01.NEU.0000255521.42579.31.

Reference Type: BACKGROUND

PMID: 17762735 (View on PubMed)

Fiorella D, Woo HH. Emerging endovascular therapies for symptomatic intracranial atherosclerotic disease. Stroke. 2007 Aug;38(8):2391-6. doi: 10.1161/STROKEAHA.107.482752. Epub 2007 Jun 21. No abstract available.

Reference Type: BACKGROUND

PMID: 17585085 (View on PubMed)

Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, Gupta R, Kirshner H, Megerian JT, Lesko J, Pitzer P, Ramos J, Castonguay AC, Barnwell S, Smith WS, Gress DR; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015 Mar 24-31;313(12):1240-8. doi: 10.1001/jama.2015.1693.

Reference Type: DERIVED

PMID: 25803346 (View on PubMed)

Other Identifiers

G080051

Identifier Type: -

Identifier Source: secondary_id

VISSIT CA-2007-01

Identifier Type: -

Identifier Source: org_study_id